Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Oligometastatic Prostate Cancer 1Cholangiocarcinoma 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × quemliclustat × Clear all
NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Big Ten Cancer Research Consortium

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT05915442 2025-05-20

SBRT-AMICO

Columbia University

Phase 2 Recruiting
23 enrolled
Genitourinary

Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡